MedTrace Logo

Predictive Validity of the Personal and Social Performance Scale for PANSS Outcomes in Schizophrenia

NCT07445217 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 763

Last updated 2026-03-03

No results posted yet for this study

Summary

The Positive and Negative Syndrome Scale (PANSS) is a widely used instrument for assessing symptom severity in schizophrenia, whereas the Personal and Social Performance Scale (PSP) provides a practical measure of functional outcomes. This study aimed to evaluate the predictive validity of the PSP for PANSS outcomes in individuals with schizophrenia.

A total of 763 patients diagnosed with schizophrenia and receiving paliperidone treatment were recruited in a 12-week multicenter prospective study. Among participants with a baseline PANSS score greater than 90, those with a 12-week PSP score above 60 were more likely to achieve a reduction of more than 20% in PANSS scores, whereas those with a PSP score below 60 showed less improvement.

Conditions

  • Functional Outcomes

Interventions

DRUG

This study employed a 12-week, multicenter, prospective research design focusing on the administration of the antipsychotic medication paliperidone.

Assessments were conducted at baseline, week 4, and week 12. Two widely used scales-the PANSS and PSP-were utilized to evaluate patients before and after treatment, followed by a correlation analysis of the results.

Sponsors & Collaborators

  • Calo Psychiatric Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-10
Primary Completion
2008-06-01
Completion
2008-09-04

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07445217 on ClinicalTrials.gov